Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lianqin Zhengzhu (连芩珍珠滴丸) is a traditional Chinese medicine (TCM) developed and marketed by JiangSu WuZhong Pharmaceutical Development. It is formulated as oral dropping pills (滴丸) and is an approved product within the company's pharmaceutical portfolio. While the specific active ingredients and biological targets are not explicitly detailed in the provided corporate materials, the name suggests a formulation likely containing *Coptis chinensis* (Lian), *Scutellaria baicalensis* (Qin), and Pearl (Zhengzhu), which are traditionally used in Chinese medicine for their heat-clearing and detoxifying properties. It is indicated for unspecified traditional medicine conditions and is part of a broader portfolio that includes both modern genetic/chemical drugs and traditional formulations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lianqin Zhengzhu.